Statin therapy on pulmonary function in patients with COPD: a meta-analysis of randomized controlled trials
Zhou Yi,Wang Jun,Zhang Long
DOI: https://doi.org/10.5246/jcps.2018.04.029
2018-01-01
Journal of Chinese Pharmaceutical Sciences
Abstract:In the current meta-analysis, we aimed to investigate the therapeutic effects of statins on pulmonary function in patients with chronic obstructive pulmonary disease (COPD). MEDLINE, EMBASE and Cochrane Central Register of clinical trials were systematically searched until January 2017 for RCTs of statins. Only trials with COPD patients were included. The I2 statistic was used to measure heterogeneity between trials and calculated mean differences for pulmonary function parameters with fixed-effect meta-analysis. Eight eligible studies with 534 participants were identified. Statin therapy had no remarkable influence on FEV1 (SMD -0. 01, 95％ CI -0. 204 to 0. 184, I2 = 0. 0％, P = 0. 922, n = 409), FEV1/ FVC (SMD 0. 163, 95％ CI -0. 044 to 0. 369, I2 = 0. 0％, P=0. 123, n = 364), 6MWD, heart rate or CRP. However, exercise time on treadmill was remarkably improved by statin therapy (SMD 1. 271, 95％ CI 0. 930 to 1. 612, I2 = 0. 0％, P = 0. 000, n = 160). Subgroup analysis showed significant, ameliorative effect of pravastatin on FEV1/FVC (SMD 0. 362, 95％ CI 0. 049 to 0. 674, I2 = 0. 0％, P = 0. 023). The results of this meta-analysis showed non-significant effect of statins on pulmonary function in COPD patients. Based on the studies reviewed, it is not recommended to prescribe statins for COPD patients without CVD risk factors due to lack of clearly defined benefit.